medrxiv
preprint
interpret
meplazumab
effici
improv
recoveri
patient
pneumonia
favor
safeti
profil
result
support
carri
largescal
investig
meplazumab
treatment
pneumonia
background
novel
human
coronaviru
specif
antivir
drug
prove
hostcellexpress
could
bind
spike
protein
involv
host
cell
invas
antibodi
could
block
infect
aim
assess
efficaci
safeti
meplazumab
human
antibodi
addon
therapi
patient
pneumonia
method
patient
receiv
recommend
strategi
diagnosi
treatment
novel
coronaviru
diseas
releas
nation
health
commiss
china
elig
patient
addon
administ
mg
meplazumab
intraven
day
patient
hospit
period
observ
concurr
control
endpoint
includ
virolog
clearanc
rate
case
sever
chest
radiograph
laboratori
test
trial
approv
ethic
committe
institut
tangdu
hospit
regist
clinicaltrialsgov
nct
find
patient
enrol
assign
meplazumab
group
feb
feb
hospit
patient
serv
concurr
control
baselin
characterist
gener
balanc
across
two
group
compar
control
group
meplazumab
treatment
significantli
improv
discharg
case
sever
critic
sever
patient
time
viru
neg
meplazumab
group
reduc
control
group
median
ci
vs
ci
percentag
patient
recov
normal
lymphocyt
count
crp
concentr
also
increas
remark
rapidli
meplazumab
group
advers
effect
found
meplazumabtr
patient
coronaviru
envelop
posit
strand
rna
viru
belong
famili
cornonavirida
order
nidoviral
past
year
two
human
coronavirus
sarscov
merscov
report
lead
sever
fatal
lower
respiratori
tract
infect
dec
outbreak
respiratori
syndrom
detect
china
caus
novel
coronaviru
name
genom
sequenc
show
belong
betacoronaviru
genu
extrem
high
homolog
sarscov
genom
proteom
ill
onset
among
rapidli
increas
number
china
globe
indic
contagi
sarscov
merscov
infect
lead
acut
viral
exud
pneumonia
multipl
organ
damag
especi
lung
present
bilater
diffus
alveolar
damag
cellular
fibromyxoid
exud
case
mild
symptom
includ
nonpneumonia
mild
pneumonia
case
patient
develop
sever
pneumonia
acut
respiratori
distress
syndrom
attribut
death
mar
case
death
report
global
current
standard
treatment
includ
oxygen
therapi
antivir
treatment
fluid
manag
antimicrobi
therapi
secondari
bacteri
infect
although
sever
drug
remdesivir
chloroquin
phosphat
regist
ongo
clinic
trial
specif
antivir
drug
novel
coronaviru
approv
far
latest
report
indic
infect
increas
express
level
multipl
proinflammatori
cytokin
includ
serum
suggest
inflamm
storm
may
involv
progress
therefor
inhibit
viru
replic
limit
excess
inflamm
equal
import
therapi
angiotensinconvert
enzym
report
host
cellular
receptor
knowledg
present
variou
human
tissu
includ
alveolar
epitheli
cell
endotheli
cell
arteri
vein
smooth
muscl
cell
etc
current
publish
data
show
direct
interact
spike
protein
type
transmembran
glycoprotein
express
epitheli
cell
human
monoclon
antibodi
meplazumab
effect
inhibit
replic
virusinduc
cytopath
effect
vero
cell
dosedepend
manner
data
demonstr
novel
entri
viru
infect
mediat
receptor
also
present
activ
inflammatori
cell
particip
regul
cytokin
secret
leukocyt
chemotaxi
bind
cyclophilin
cypa
cypa
proinflammatori
cytokin
upregul
respons
viru
infect
previou
studi
demonstr
antibodi
target
inhibit
cypainduc
cell
chemotaxi
thu
attenu
local
inflamm
base
evid
assess
clinic
outcom
use
meplazumab
addon
therapi
patient
pneumonia
design
openlabel
concurr
control
trial
evalu
whether
meplazumab
infus
improv
patient
pneumonia
inhibit
viru
replic
suppress
inflamm
hope
studi
shed
light
find
new
drug
strategi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
control
novel
coronavirusinduc
pneumonia
prospect
singl
center
openlabel
trial
tangdu
hospit
fourth
militari
medic
univers
xian
china
studi
protocol
consent
approv
independ
ethic
committe
institut
nation
drug
clinic
trial
tangdu
hospit
studi
regist
clinicaltrialsgov
patient
enrol
enrol
patient
fulfil
inclus
exclus
criteria
inclus
criteria
follow
men
women
age
year
patient
common
sever
critic
pneumonia
laboratori
clinic
diagnos
accord
diagnosi
treatment
novel
coronaviru
diseas
releas
nation
health
commiss
china
subject
must
understand
studi
will
particip
studi
exclus
criteria
follow
allerg
reaction
histori
allergi
ingredi
treat
trial
patient
suitabl
particip
studi
judgment
investig
patient
sign
inform
consent
form
enrol
case
sever
categor
common
sever
critic
vital
sign
oxygen
index
chest
radiograph
vital
organ
function
base
diagnosi
treatment
novel
coronaviru
diseas
common
case
featur
fever
respiratori
symptom
radiograph
pneumonia
sever
case
character
follow
sign
dyspnea
respiratori
frequenc
blood
oxygen
satur
ratio
critic
case
character
follow
sign
respiratori
failur
need
mechan
ventil
shock
multipl
organ
dysfunctionfailur
need
intens
care
unit
icu
patient
met
follow
criteria
discharg
bodi
temperatur
recov
remain
normal
day
respiratori
symptom
relief
two
continu
neg
nasopharyng
swab
test
interv
hour
period
hospit
patient
center
observ
concurr
control
requir
follow
inclus
exclus
criteria
mention
enrol
patient
receiv
recommend
treatment
accord
diagnosi
treatment
novel
coronaviru
diseas
physician
allow
use
necessari
treatment
laboratori
radiograph
examin
standard
care
clinic
laboratori
radiograph
assess
conduct
baselin
includ
complet
blood
count
serum
biochem
test
renal
function
liver
function
c
reactiv
protein
crp
serum
electrolyt
test
coagul
analysi
pt
aptt
inr
fib
ddimer
chest
ctchest
xray
nasopharyng
swab
test
use
qrtpcr
assay
approv
nation
medic
product
administr
studi
visit
baselin
day
meplazumab
administ
day
day
day
intraven
infus
within
min
efficaci
safeti
assess
baselin
everi
day
day
day
everi
week
thereaft
day
discharg
primari
studi
endpoint
virolog
clearanc
ie
neg
conserv
rate
time
neg
use
qrtpcr
nasopharyng
swab
sampl
secondari
efficaci
endpoint
assess
time
recoveri
vital
sign
includ
bodi
temperatur
respiratori
rate
chest
radiograph
improv
rate
recoveri
time
day
discharg
inflamm
recoveri
percentag
patient
normal
crp
concentr
continu
variabl
express
median
iqr
compar
mannwhitney
u
test
categor
variabl
express
number
compar
fisher
exact
test
ordin
regress
mcnemar
test
stack
column
drawn
describ
composit
case
sever
chest
radiograph
improv
lymphocyt
count
crp
concentr
differ
discharg
viru
nucleic
acid
neg
convers
curv
analyz
logrank
mantelcox
test
twosid
less
consid
statist
signific
statist
analys
perform
use
spss
softwar
version
graphpad
prism
softwar
version
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
feb
feb
screen
patient
diagnos
tangdu
hospit
reason
screen
failur
list
figur
patient
sign
inform
consent
alloc
meplazumab
group
hospit
patient
met
inclus
criteria
exclus
criteria
sign
collect
concurr
control
period
demograph
comorbid
epidemiolog
exposur
prescrib
treatment
sign
symptom
case
sever
gener
balanc
across
two
group
shown
tabl
median
age
patient
year
iqr
meplazumab
group
year
iqr
control
group
patient
group
epidemiolog
exposur
histori
underli
comorbid
includ
diabet
hypertens
cardiovascular
diseas
parkinson
diseas
observ
patient
meplazumab
control
group
respect
patient
receiv
recommend
therapi
accord
diagnosi
treatment
novel
coronaviru
diseas
includ
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
antivir
treatment
glucocorticoid
treatment
antibiot
treatment
common
case
sever
case
critic
case
enrol
meplazumab
group
contrast
common
case
sever
case
critic
case
collect
control
group
show
differ
compar
meplazumab
group
subsequ
patient
receiv
dose
meplazumab
patient
receiv
dose
meplazumab
distribut
case
sever
discharg
case
analyz
group
day
followup
shown
tabl
overal
improv
rate
defin
percentag
discharg
improv
case
day
meplazumab
group
control
group
respect
one
aggrav
case
observ
control
group
day
end
observ
day
group
show
signific
improv
compar
baselin
p
meplazumab
control
recoveri
sever
critic
case
paramount
import
reduc
mortal
observ
addon
therapeut
efficaci
meplazumab
sever
critic
case
analyz
time
discharg
result
shown
figur
indic
meplazumab
treatment
improv
discharg
sever
critic
case
significantli
compar
control
group
discharg
case
observ
followup
period
control
group
case
sever
sever
critic
case
group
improv
significantli
compar
baselin
sinc
day
posttreat
figur
particular
day
sever
case
critic
case
improv
common
case
discharg
control
group
meplazumab
group
case
sever
critic
discharg
critic
case
improv
common
critic
case
improv
sever
demonstr
significantli
benefici
outcom
compar
control
group
tabl
figur
result
indic
meplazumab
treatment
acceler
improv
make
rapid
recoveri
pneumonia
especi
sever
critic
case
trial
death
report
patient
chest
radiograph
analysi
perform
independ
two
radiologist
grade
chang
area
groundglass
opac
consolid
compar
baselin
shown
figur
chest
radiograph
compar
baselin
two
group
improv
gradual
day
day
meplazumab
group
case
improv
case
improv
patient
improv
control
group
day
patient
meplazumab
group
improv
similar
situat
observ
control
group
day
case
improv
case
improv
meplazumab
group
case
improv
case
improv
control
group
meplazumab
group
show
signific
benefit
control
group
day
respect
coincid
improv
case
sever
repres
chest
ct
imag
meplazumabtr
patient
shown
figur
display
ct
imag
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
manifest
bilater
groundglass
shadow
consolid
baselin
period
lesion
resolv
day
posttreat
trial
clearanc
viru
evalu
negativeconvers
rate
time
neg
day
rate
viru
nucleic
acid
neg
convers
control
group
reach
day
rate
meplazumab
group
day
reach
day
significantli
higher
control
group
respect
analysi
time
viru
neg
indic
meplazumabtr
patient
convert
neg
shorter
period
patient
control
group
significantli
median
ci
vs
ci
figur
data
indic
obviou
benefit
meplazumab
treatment
clearanc
report
lymphocytopenia
typic
characterist
correl
prognosi
pneumonia
studi
compar
lymphocyt
count
baselin
posttreat
group
shown
figur
observ
period
day
percentag
patient
normal
lymphocyt
count
l
increas
group
improv
meplazumab
group
notabl
compar
baselin
percentag
meplazumab
group
improv
significantli
earli
day
signific
differ
detect
control
group
followup
period
also
measur
concentr
crp
predictor
sever
shown
figur
day
day
percentag
patient
normal
crp
concentr
increas
indic
signific
increas
compar
baselin
p
day
control
group
signific
increas
observ
day
day
compar
baselin
data
suggest
meplazumab
exhibit
effect
control
virusinduc
acut
inflamm
earli
manag
meplazumab
group
elev
alt
ast
uln
report
patient
control
group
alt
ast
elev
report
case
singl
alt
elev
report
case
increas
level
alt
ast
return
normal
day
four
patient
treatment
procedur
affect
fluctuat
abnorm
transaminas
relat
meplazumab
treatment
comprehens
judgement
investig
advers
event
report
meplazumabtr
patient
includ
reaction
around
inject
site
rash
nausea
vomit
anemia
neutropenia
thrombocytopenia
total
bilirubin
albumin
creatinin
etc
rapid
escal
countri
report
case
world
mar
clinic
trial
regist
clinicaltrialgov
nearli
one
fifth
reagent
small
molecular
compound
remdesivir
oseltamivir
four
antibodi
drug
like
block
antibodi
bevacizumab
eculizumab
meplazumab
report
addon
trial
use
human
monoclon
antibodi
meplazumab
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
novel
pharmacolog
mechan
treat
pneumonia
block
viru
invas
attenu
inflamm
ad
meplazumab
mg
patient
receiv
recommend
treatment
increas
virolog
clearanc
rate
promot
recoveri
chest
radiograph
lymphocytopenia
decreas
inflamm
index
crp
acceler
improv
diseas
without
seriou
advers
event
recent
publish
studi
reveal
novel
identifi
receptor
infect
bind
spike
protein
infect
effici
inhibit
meplazumab
target
dose
depend
manner
result
provid
insight
act
function
entri
receptor
serv
therapeut
target
inhibit
viru
infect
report
case
categor
sever
critic
case
fatal
rate
critic
case
studi
reveal
great
challeng
enhanc
therapeut
effect
sever
case
focu
conduct
effect
intervent
earli
possibl
addon
trial
introduc
novel
therapi
target
block
viru
infect
inflamm
favor
efficaci
meplazumab
treatment
acceler
improv
especi
sever
critic
case
day
sever
critic
case
discharg
death
case
report
improv
chest
imag
clearanc
viru
recov
lymphocyt
count
observ
within
week
manag
indic
therapeut
effect
facilit
prognosi
receptor
ligand
cypa
interact
key
inflamm
chemotaxi
cypa
secret
extracellular
respons
inflammatori
stimuli
eg
viru
infect
activ
attract
leukocyt
via
receptor
stimulu
site
demonstr
antibodi
could
attenu
chemotact
index
cell
induc
cypa
multipl
cytokin
chemokin
increas
significantli
patient
significantli
correl
pulmonari
inflamm
index
chest
ct
imag
result
suggest
excess
immun
cell
migrat
lung
tissu
may
caus
uncontrol
immun
respons
lead
inflamm
storm
aggrav
diseas
presum
meplazumab
block
interact
cypa
attenu
chemotact
effect
cypa
decreas
immun
cell
lung
tissu
facilit
improv
chest
radiograph
trial
remark
rapid
resolut
inflammatori
foci
lung
like
groundglass
opac
consolid
observ
meplazumab
treatment
group
lymphopenia
common
patient
sar
patient
use
indic
diseas
sever
prognosi
patient
report
lymphopenia
due
absenc
lymphocyt
propos
lymphocytopenia
sar
patient
caus
indirect
mechan
includ
inflamm
storm
vascular
cell
adhes
solubl
fa
ligand
glucocorticoid
howev
sarscov
particl
genom
sequenc
detect
larg
number
circul
lymphocyt
caus
destruct
lymphocyt
trial
lymphocyt
count
meplazumabtr
patient
restor
short
time
high
express
activ
cell
may
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
facilit
invas
lymphocyt
bind
spike
protein
suggest
may
involv
lymphocytopenia
meplazumab
interrupt
process
prevent
viru
invas
keep
lymphocyt
surviv
second
meplazumab
block
interact
might
contribut
lymphocyt
elev
peripher
blood
inhibit
lymphocyt
accumul
pulmonari
organ
summari
establish
specif
antibodi
addon
therapi
model
combin
therapeut
strategi
specif
antibodi
recommend
antiviru
treatment
demonstr
safe
effect
effect
dosag
antibodi
time
administr
attenu
inflamm
patient
facilit
patient
get
acut
exud
pneumonia
therefor
antibodi
therapi
extend
therapeut
window
thu
safeguard
patient
pass
danger
period
favor
specif
antibodi
drug
inhibit
viru
replic
suppress
inflamm
storm
meplazumab
antibodi
block
receptor
host
cell
inhibit
viru
invas
replic
interrupt
spike
protein
recogn
receptor
meanwhil
meplazumab
block
receptor
proinflammatori
factor
cypa
thu
suppress
inflamm
although
get
outcom
meplazumab
treatment
result
limit
small
subject
size
absenc
parallel
control
therefor
confirm
larger
scale
random
doubleblind
placebocontrol
trial
requir
fulli
assess
efficaci
safeti
meplazumab
patient
pneumonia
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
p
valu
compar
meplazumab
control
day
ordin
regress
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
